[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR025060A1 - Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa - Google Patents

Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa

Info

Publication number
AR025060A1
AR025060A1 ARP000104064A ARP000104064A AR025060A1 AR 025060 A1 AR025060 A1 AR 025060A1 AR P000104064 A ARP000104064 A AR P000104064A AR P000104064 A ARP000104064 A AR P000104064A AR 025060 A1 AR025060 A1 AR 025060A1
Authority
AR
Argentina
Prior art keywords
hydroxypropilmetilcellulose
capsules
pharmaceutical formulations
formulations
solubilized
Prior art date
Application number
ARP000104064A
Other languages
English (en)
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of AR025060A1 publication Critical patent/AR025060A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulacion farmacéutica oral que comprende, en una cápsula de hidroxipropilmetilcelulosa, un análogo de camptotecina dispersado o solubilizado en unamatriz semi-solida. Estas formulaciones son utiles para el tratamiento de enfermedadesneoplásic as.
ARP000104064A 1999-08-10 2000-08-07 Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa AR025060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918885.6A GB9918885D0 (en) 1999-08-10 1999-08-10 Pharmaceutical formulations in hydroxypropymethycellulose capsules

Publications (1)

Publication Number Publication Date
AR025060A1 true AR025060A1 (es) 2002-11-06

Family

ID=10858930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104064A AR025060A1 (es) 1999-08-10 2000-08-07 Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa

Country Status (18)

Country Link
US (1) US6569452B1 (es)
EP (1) EP1126851B1 (es)
CN (1) CN1245976C (es)
AR (1) AR025060A1 (es)
AT (1) ATE262905T1 (es)
AU (1) AU6158200A (es)
CA (1) CA2354039C (es)
CO (1) CO5200854A1 (es)
CZ (1) CZ293749B6 (es)
DE (1) DE60009442D1 (es)
EA (1) EA200100568A1 (es)
GB (1) GB9918885D0 (es)
HK (1) HK1040930B (es)
HU (1) HUP0104476A3 (es)
IL (2) IL143502A0 (es)
NO (1) NO319712B1 (es)
PE (1) PE20010407A1 (es)
WO (1) WO2001010443A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
CN1316970C (zh) * 2002-11-14 2007-05-23 武汉华中科大纳米药业有限公司 一种羟喜树碱固体分散物及其制剂
JP2005183361A (ja) * 2003-10-03 2005-07-07 Ngk Insulators Ltd 電子放出素子、電子放出装置、ディスプレイ及び光源
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
CN101516346B (zh) * 2006-09-26 2012-05-23 株式会社三养社 水不溶性喜树碱衍生物的亚微粒纳米颗粒及其制备方法
CA2844367C (en) * 2011-06-24 2016-02-16 Acenda Pharma, Inc. Method and improved pharmaceutical composition for improving the absorption of an ester prodrug
CN103110605A (zh) * 2011-11-17 2013-05-22 天士力制药集团股份有限公司 一种热熔胶囊制剂及其制备方法
CN106103451B (zh) * 2014-01-17 2019-10-29 昂科拉制药有限公司 用于治疗癌症的伊立替康的固体口服剂型
CN105287427B (zh) * 2015-10-20 2017-04-19 沈阳红旗制药有限公司 一种利福平半固体胶囊及其制备方法
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
EP0758237B1 (en) 1994-04-28 2003-08-27 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin or 7-ethyl camptothecin in dimethylisosorbide or dimethylacetamide
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6214378B1 (en) 1996-08-02 2001-04-10 Hisamitsu Pharmaceutical Co., Inc. Capsules for oral preparations and capsule preparations for oral administration
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina

Also Published As

Publication number Publication date
NO319712B1 (no) 2005-09-05
EP1126851A1 (en) 2001-08-29
CN1245976C (zh) 2006-03-22
CA2354039C (en) 2008-09-23
HK1040930A1 (en) 2002-06-28
IL143502A0 (en) 2002-04-21
AU6158200A (en) 2001-03-05
PE20010407A1 (es) 2001-03-28
HUP0104476A3 (en) 2004-05-28
GB9918885D0 (en) 1999-10-13
IL143502A (en) 2006-12-10
WO2001010443A1 (en) 2001-02-15
NO20013205L (no) 2001-06-26
CO5200854A1 (es) 2002-09-27
EP1126851B1 (en) 2004-03-31
CZ293749B6 (cs) 2004-07-14
CA2354039A1 (en) 2001-02-15
HK1040930B (zh) 2006-10-27
CZ20012089A3 (cs) 2001-10-17
US6569452B1 (en) 2003-05-27
HUP0104476A2 (hu) 2002-03-28
EA200100568A1 (ru) 2001-10-22
NO20013205D0 (no) 2001-06-26
DE60009442D1 (de) 2004-05-06
CN1327387A (zh) 2001-12-19
ATE262905T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
ECSP083351A (es) Composiciones farmacéuticas
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
EE03805B1 (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
AP1954A (en) Controlled release compositions comprising nimesulide.
FI964583A0 (fi) Tokoferolikoostumuksia biologisesti aktiivisten aineiden antamiseksi
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
AR032293A1 (es) Estuche farmaceutico
ATE292453T1 (de) Antivirale arznei
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
HUP0203295A2 (hu) Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ECSP003607A (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
DE60214476D1 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon
AR031846A1 (es) Combinacion de sustancias activas, medicamentos y formulaciones que la contienen, y uso de la misma para la preparacion de un medicamento para el tratamiento del dolor
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto

Legal Events

Date Code Title Description
FB Suspension of granting procedure